Compare FuelCell Energy Inc (FCEL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Viatris Inc — how do they compare? FuelCell Energy Inc trades at $17.64 (market cap $1.47B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 13.7× FuelCell Energy Inc's market cap, and Viatris Inc pays a 2.74% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Viatris Inc for 57 Days on average.
| FCEL | VTRS | |
|---|---|---|
Market Cap | $1.47B | $20.12B |
Volume | 12,559,948 | 7,543,511 |
Sector | Industrials | Health |
52-Week High | $36.01 | $18.27 |
52-Week Low | $6.00 | $9.74 |
Typical Hold Time | 48 Days | 57 Days |
Enterprise Value | $1.05B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.245, down 16.49% over 24 hours, reflecting recent volatility amid a securities class action. The stock shows a bullish technical signal with support near $17 and resistance at $19. Fundamentally, the company reported revenue of $158.16 million for 2025 but posted a net loss of $187.90 million, with negative profit margins persisting. Cash flow improved in 2025 with net cash flow of $132.91 million, though operational cash flow remains negative.
The outlook is cautious; while analyst consensus suggests a $21.57 price target with 40% buy ratings, ongoing legal challenges and consistent losses pose significant risks. Investment opportunity hinges on execution turnaround and market adoption of hydrogen energy, but high volatility and financial instability warrant careful consideration.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
